ANA ALIANA FODOR, ALINA MIHAELA PASCU, VLADIMIR POROCH, PETRU IULIAN IFTENI, VICTORIA BURTEA, SEBASTIAN TOMA, ADRIAN BARACAN, CLAUDIA GAVRIS, ANDREEA LONG TERM EFFICACY OF THE TREATMENT WITH OLANZAPINE PAMOATE, RISPERIDONE AND ARIPIPRAZOLE MONOHYDRATE The use of long-acting injectable antipsychotics (LAIs) is considered to be an important treatment option, especially in early stages of schizophrenia. The aim of this study was to evaluate the efficacy, safety and sustained remission in schizophrenia patients treated with three of the available LAIs substances: olanzapine pamoate, risperidone microspheres and aripiprazole monohydrate. A retrospective chart review study evaluating the efficacy of LAIs compared to oral antispychotics during a five years period was performed. Of the 102 patients included in the study, 52 (50.9%) continued LAIs: olanzapine pamoate (n = 20, 38.4%), risperidone microsphere (n = 22, 42.3%), aripiprazole monohydrate (n = 10, 19.3%). In the LAIs group the number of relapses was smaller than in the oral antipsychotics group (12 vs. 23, P < 0.05) as well as the number of admissions (15 vs. 30, P < 0.05). In conclusion, relapse in schizophrenia is strongly related to nonadherence. LAIs prescription overall was underutilized despite their efficacy. Future randomized studies are needed to evaluate the long term efficacy of LAIs compared to oral treatment.